Abstract
The development of glycoprotein (GP) IIb-IIIa antagonists is reviewed with particular emphasis on the characteristics of each agent, the pharmacodynamic profile of each agent, results in pivotal clinical trials, and the associated implications. GP IIb-IIIa antagonists have greatest benefit when used as adjunctive therapy during percutaneous coronary intervention (PCI) when the patient has intra-coronary thrombosis. These agents appear to provide greatest benefit when used in combination with heparin. The clinical niche for parenteral GP IIb-IIIa antagonists is evolving but appears to be for patients in transition, such as individuals requiring emergent PCI before oral agents are fully active and for unstable patients requiring transport to PCI centers. Subsequent studies should evaluate the optimal duration of therapy with GP IIb-IIIa antagonists.
Keywords: Platelet, antiplatelet, glycoprotein IIb-IIIa, pharmacodynamics, acute coronary syndromes, hemostasis, Abciximab, pharmacodynamic assessment, Tiofiban, Eptifibatide
Current Drug Targets
Title: Current Issues with Glycoprotein IIb-IIIa Antagonists
Volume: 12 Issue: 12
Author(s): David J. Schneider
Affiliation:
Keywords: Platelet, antiplatelet, glycoprotein IIb-IIIa, pharmacodynamics, acute coronary syndromes, hemostasis, Abciximab, pharmacodynamic assessment, Tiofiban, Eptifibatide
Abstract: The development of glycoprotein (GP) IIb-IIIa antagonists is reviewed with particular emphasis on the characteristics of each agent, the pharmacodynamic profile of each agent, results in pivotal clinical trials, and the associated implications. GP IIb-IIIa antagonists have greatest benefit when used as adjunctive therapy during percutaneous coronary intervention (PCI) when the patient has intra-coronary thrombosis. These agents appear to provide greatest benefit when used in combination with heparin. The clinical niche for parenteral GP IIb-IIIa antagonists is evolving but appears to be for patients in transition, such as individuals requiring emergent PCI before oral agents are fully active and for unstable patients requiring transport to PCI centers. Subsequent studies should evaluate the optimal duration of therapy with GP IIb-IIIa antagonists.
Export Options
About this article
Cite this article as:
J. Schneider David, Current Issues with Glycoprotein IIb-IIIa Antagonists, Current Drug Targets 2011; 12 (12) . https://dx.doi.org/10.2174/138945011797635768
DOI https://dx.doi.org/10.2174/138945011797635768 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Insights into the Pervasive Role of M3 Muscarinic Receptor in Cardiac Diseases
Current Drug Targets Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry Exercise-Induced Cardiac Troponin Release: Real-Life Clinical Confusion
Current Medicinal Chemistry In Vivo Cellular Imaging for Translational Medical Research
Current Medical Imaging S1P Regulation of Macrophage Functions in the Context of Cancer
Anti-Cancer Agents in Medicinal Chemistry Synthesis, Structural Determination of a New Ocotillol Derivative and its Epimer
Letters in Organic Chemistry Editorial: [Hot Topic: Molecular Image-Guided Theranostics and Personalized Medicine]
Current Medical Imaging Mononuclear Cell Recruitment and Inflammation in Atherosclerosis
Vascular Disease Prevention (Discontinued) Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry FK506 and Its Analogs - Therapeutic Potential for Neurological Disorders
Current Drug Targets - CNS & Neurological Disorders Early Ischemic Blood Brain Barrier Damage: A Potential Indicator for Hemorrhagic Transformation Following Tissue Plasminogen Activator (tPA) Thrombolysis?
Current Neurovascular Research Exosomes: The Messengers of Health and Disease
Current Neuropharmacology Renin Angiotensin System as a Regulator of Cell Volume. Implications to Myocardial Ischemia
Current Cardiology Reviews Unique Coronary Artery Disease Differences in Women as Related to Revascularization
Current Medicinal Chemistry Mitochondrial MMP Activation, Dysfunction and Arrhythmogenesis in Hyperhomocysteinemia
Current Vascular Pharmacology Precision Percutaneous Coronary Intervention of a Complex Lesion
Reviews on Recent Clinical Trials Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients
Current Vascular Pharmacology Infection-Associated Biomarkers of Inflammation in Atherosclerosis
Current Pharmaceutical Design Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism
Current Drug Targets Subject Index To Volume 6
Cardiovascular & Hematological Disorders-Drug Targets